WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review

Date: February 8, 2017
Pages: 23
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: WCEBFCDAA7BEN
Leaflet:

Download PDF Leaflet

WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.

    Highlights

    WEX Pharmaceuticals Inc (WEX) is a clinical stage biotechnology company that focuses on the discovery, development, manufacture and commercialization of innovative drugs for pain management. The company develops a new class of non-opioid analgesics utilizing its proprietary platform technology TTX (Tetrodotoxin or TTX). TTX is a non-peptide neurotoxin, non-addictive alternative to opioids, and a sodium channel blocker. WEX’s clinical candidates include TEC-006 and TTX-CINP-201. TEC-006 is being studied for the treatment of moderate to severe cancer related pain and TTX-CINP-201 is being developed for moderate to severe neuropathic pain caused by chemotherapy in patients with cancer. WEX is headquartered in Vancouver, British Columbia, Canada.

    Reasons to Buy
    • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
    • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
    • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
    • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
    Note: Some sections may be missing if data is unavailable for the company.
  • SECTION 1 - ABOUT THE COMPANY

    WEX Pharmaceuticals Inc - Key Facts
    WEX Pharmaceuticals Inc - Key Employees
    WEX Pharmaceuticals Inc - Major Products and Services
    WEX Pharmaceuticals Inc - Pharmaceutical Pipeline Products Data
    WEX Pharmaceuticals Inc, Pipeline Products by Therapy Area
    WEX Pharmaceuticals Inc, Pipeline Products by Development Phase
    WEX Pharmaceuticals Inc - History
    WEX Pharmaceuticals Inc - Locations And Subsidiaries
    Head Office

    SECTION 2 – COMPANY ANALYSIS

    WEX Pharmaceuticals Inc - Business Description
    WEX Pharmaceuticals Inc - Corporate Strategy
    WEX Pharmaceuticals Inc - SWOT Analysis
    SWOT Analysis - Overview
    WEX Pharmaceuticals Inc - Strengths
    WEX Pharmaceuticals Inc - Weaknesses
    WEX Pharmaceuticals Inc - Opportunities
    WEX Pharmaceuticals Inc - Threats
    WEX Pharmaceuticals Inc - Key Competitors

    SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

    WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
    WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
    WEX Pharmaceuticals Inc, Recent Deals Summary

    SECTION 4 – APPENDIX

    Methodology
    About GlobalData
    Contact Us
    Disclaimer

    LIST OF TABLES

    WEX Pharmaceuticals Inc, Key Facts
    WEX Pharmaceuticals Inc, Key Employees
    WEX Pharmaceuticals Inc, Major Products and Services
    WEX Pharmaceuticals Inc, Number of Pipeline Products by Therapy Area
    WEX Pharmaceuticals Inc, Number of Pipeline Products by Development Stage
    WEX Pharmaceuticals Inc, History
    WEX Pharmaceuticals Inc, Key Competitors
    WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
    WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
    WEX Pharmaceuticals Inc, Recent Deals Summary

    LIST OF FIGURES

    WEX Pharmaceuticals Inc, Pipeline Products by Therapy Area
    WEX Pharmaceuticals Inc, Pipeline Products by Development Phase
    WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
    WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

    COMPANIES MENTIONED

    PainCeptor Pharma Corp
    IntelGenx Corp
    EquiTech Corp
    Aquinox Pharmaceuticals Inc
    Skip to top


    Ask Your Question

    WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: